All manuscripts
Publications B Cells CAR T Cells CD34 Cells NK Cells T-Cells Treg Cells γδ T G-Rex®100M

High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails

Published Journal Nature Biotechnology

Share
No image preview

Overview

Describes a non-viral CRISPR/Cas9 method using ssCTS templates for high-yield CAR-T production. A GMP-compatible process was developed where cells were expanded in G-Rex® 100M gas-permeable culture vessels for 7-10 days.

What this paper found

Hybrid repair templates that combine a long single-stranded DNA body with short double-stranded Cas9 target sites raised knock-in efficiency and live knock-in cell yield in primary human cells, generating up to sevenfold more knock-in cells than fully double-stranded templates at optimal concentrations. In T cells these templates reached 78.5% knock-in for a roughly 1.5 kb tNGFR construct and 39% for a roughly 2.9 kb BCMA-CAR construct at the TRAC locus. Across 44 constructs targeting 22 loci, adding the M3814, trichostatin A and XL413 cocktail raised knock-in efficiency by roughly 2.5-fold on average. A GMP-compatible run electroporated 100 × 10^6 T cells on day 2 and expanded them in G-Rex® 100M vessels, giving 40.4% knock-in on day 7 and more than 1.5 × 10^9 CAR-positive cells by day 10.

Note: Adding the small-molecule inhibitors pushed knock-in above 60% but lowered live cell counts, so the final yield of CAR-positive cells fell below that reached with the ssCTS templates alone; the authors state that further work is needed to see whether this toxicity can be mitigated.

Average knock-in efficiencies were 40.4% on day 7 and 45.8% on day 10 — Brian R. Shy, Vivasvan S. Vykunta, Alvin Ha, Alexis Talbot, Theodore L. Roth, David N. Nguyen, Wolfgang G. Pfeifer, Yan Yi Chen, Franziska Blaeschke, Eric Shifrut, Shane Vedova, Murad R. Mamedov, Jing-Yi Jing Chung, Hong Li, Ruby Yu, David Wu, Jeffrey Wolf, Thomas G. Martin, Carlos E. Castro, Lumeng Ye, Jonathan H. Esensten, Justin Eyquem, Alexander Marson, Nature Biotechnology

Study details

Authors
Brian R. Shy, Vivasvan S. Vykunta, Alvin Ha, Alexis Talbot, Theodore L. Roth, David N. Nguyen, Wolfgang G. Pfeifer, Yan Yi Chen, Franziska Blaeschke, Eric Shifrut, Shane Vedova, Murad R. Mamedov, Jing-Yi Jing Chung, Hong Li, Ruby Yu, David Wu, Jeffrey Wolf, Thomas G. Martin, Carlos E. Castro, Lumeng Ye, Jonathan H. Esensten, Justin Eyquem, Alexander Marson
Institution
Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA · Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA · Department of Medicine, University of California San Francisco, San Francisco, CA, USA · Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA · Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA · Parker Institute for Cancer Immunotherapy, University of California San Francisco, San Francisco, CA, USA · INSERM U976, Saint Louis Research Institute, Paris City University, Paris, France · Medical Scientist Training Program, University of California San Francisco, San Francisco, CA, USA · Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH, USA · Department of Physics, The Ohio State University, Columbus, OH, USA · Department of Research and Development, Reagent and Services Business Unit, Life Science Group, GenScript Biotech, Nanjing, China · UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA · Biophysics Graduate Program, The Ohio State University, Columbus, OH, USA · Institute of Human Genetics, University of California San Francisco, San Francisco, CA, USA · Chan Zuckerberg Biohub, San Francisco, CA, USA · Diabetes Center, University of California San Francisco, San Francisco, CA, USA
Journal
Nature Biotechnology
Year
2022
PMID / PMC
PMID: 36008610 · PMC
G-Rex® model(s)
G-Rex®100M
Cell type(s)
B Cells, CAR T Cells, CD34 Cells, NK Cells, T-Cells, Treg Cells, γδ T
Application area
Hematologic malignancy · Other
Study phase
Preclinical

How G-Rex® was used

In the GMP-compatible scale-up, roughly 100 × 10^6 primary human T cells from two healthy donors were activated on day 0 with CD3/CD28 Dynabeads plus IL-7 and IL-15, then electroporated on day 2 with Cas9 RNPs and ssCTS templates in Maxcyte R-1000 cuvettes. The electroporated cells were transferred to G-Rex® 100M gas-permeable culture vessels (Wilson Wolf) and expanded for a total of 7 or 10 days, with 100 U/ml IL-7 and 10 U/ml IL-15 added every 2 to 3 days. Day 10 cultures reached an average BCMA-CAR knock-in of 45.8% and more than 1.5 × 10^9 CAR-positive cells for both donors.

Note: The gas-permeable vessels were used for the GMP-compatible scale-up arm; the smaller optimization and screening experiments were expanded in 96-well plates with the cultures split every 2 to 3 days.

Explore related

Full citation

Shy BR, Vykunta VS, Ha A, et al. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nat Biotechnol. 2023;41(4):521-531.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →